舒莱在肾移植免疫诱导治疗中有效性和安全性研究  

Efficacy and safety of simulect in renal transplation recipients treated with induction therapy

作　　者：郑凯[1] 谭建明[1] 吴卫真[1] 杨顺良[1] 徐廷昭[1] 

机构地区：[1]南京军区福州总医院全军器官移植中心,福州350025

出　　处：《免疫学杂志》2007年第5期556-558,共3页Immunological Journal

基　　金：福建省自然科学基金资助项目(C0510033)

摘　　要：目的探讨在肾移植免疫诱导治疗中巴利昔单抗(舒莱)的有效性和安全性。方法随机选取69例肾移植受者,在常规三联免疫抑制方案的基础上,分别接受舒莱或ATG诱导治疗,对比观察两组的人/肾存活率、排斥反应以及包括感染在内的药物相关副作用的差异。结果接受舒莱的患者组药物相关副作用显著低于接受ATG的患者组(P<0.05),两组患者的人/肾存活率、急性排斥反应和肺部感染的发生率均无显著差异(P>0.05)。移植物功能(移植后血肌酐水平及下降速度)在移植早期舒莱组优于ATG组,而长期随访结果显示两组之间无显著差异。结论肾移植受者接受巴利昔单抗(舒莱)免疫诱导治疗是安全和有效的,与ATG诱导治疗方法比较具有更少的副作用。Objective To evaluate the efficacy and the safety of BasiliXimab （Simulect） as part of a quadruple induction regimen. Methods Sixty-nine recipients of kidney transplants received either Simulect or ATG in addition to the standard immunosuppressive protocol. Results Patients treated with Simulect had a significantly lower incidence of drug-related side effects （ P 〈 0.05） when compared with patients treated with ATG. The incidence of rejection episodes and infectious complications was not different between the two groups. Patient survival did not differ significantly between the two groups. Analysis of graft function showed an advantage for the Simulect group in terms of postoperative serum creatinine levels. However, no differences were observed in long-term follow-up between the two groups. Conclusion Our results indicate that treatment with Simulect as induction therapy in Kidney transplantation is safe and effective and shows fewer side effects when compared with induction therapy including ATG.

关 键 词：舒莱 ATG 肾移植 诱导治疗 

分 类 号：R699[医药卫生—泌尿科学]